What we do:

Amagma is developing antibody therapies to treat human diseases driven by enzyme hyperactivity.  In many inflammatory conditions, overactive extracellular proteases trigger tissue damage that can sustain broad inflammatory responses. Using state-of-the-art antibody discovery and optimization strategies, we can selectively target domains of these enzymes and block their activity. Our ability to identify highly specific and differentiated antibodies allows us to overcome the challenges historically associated with this target class.

Management Team

Tillman Gerngross, Ph.D.

Tillman Gerngross, Ph.D.

President and Co-Founder

Leonard Zon, M.D.

Leonard Zon, M.D.

Co-Founder

Jennifer Dovey, Ph.D.

Jennifer Dovey, Ph.D.

VP Biology

Daniel M. Horowitz, Ph.D.

Daniel M. Horowitz, Ph.D.

VP Operations & Finance

Allan D. Capili, Ph.D.

Allan D. Capili, Ph.D.

Senior Director, Biologics

Board of Directors

Amy Shulman

Amy Shulman

Director, Polaris Ventures

Tillman Gerngross, Ph.D.

Tillman Gerngross, Ph.D.

Co-founder, Chair

Phil Ferneau

Phil Ferneau

Borealis Ventures

Leonard Zon, M.D.

Leonard Zon, M.D.

Co-founder, Observer

Click here for a list of current Amagma job openings.